Brought to you by 
Passage Bio closes $110mm Series B round
06 Sep 2019
Executive Summary
Passage Bio (AAV-delivered gene therapies for rare monogenic CNS diseases) closed a $110mm Series B financing round led by life sciences investment firm Access Biotechnology (added a board member), which was joined by returning backers OrbiMed, Frazier Healthcare Partners, Versant Ventures, Lily Asia Ventures, New Leaf Venture Partners, and Vivo Capital, along with new investors Boxer Capital of Tavistock Group, Highline Capital Management, Logos Capital, and Sphera Funds Management. Launched earlier this year with a $115.5mm Series A round, Passage will use the proceeds to support further development of its five pipeline programs in-licensed from UPenn. Clinical trials for its lead candidates in GM1 gangliosidosis and frontotemporal dementia are expected in 1H 2020.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Passage Bio closes $110mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice